Rice bran supplement for mouth sores caused by radiation in head and neck cancer
Tests rice bran supplements for mouth sores during radiation treatment for head and neck cancer.
Plain-language title generated from the registry record
Registry title: Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
Key facts
- Where
- Cairo, EgyptSee the site
Where in Egypt
- German university in cairoCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christina Milad Lobos
- Trial code
- NCT07242859
- Record updated
- 21 November 2025
- Original description
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy. The trial will include adult patients undergoing radiation treatment. Participants will be given rice bran supplements during their therapy to see if it can lessen these side effects and improve their overall quality of life.Read full original descriptionShow less
Effects of Rice Bran on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer and Its Impact on the Quality of Life
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy. The trial will include adult patients undergoing radiation treatment. Participants will be given rice bran supplements during their therapy to see if it can lessen these side effects and improve their overall quality of life.
Inclusion: Male or female patients of age 18 years old tor more; Patients with squamous cell carcinomas without metastases of other non-head and non-neck tumors; Patients undergoing radiotherapy with an ECOG performance status of 0, 1, or 2; Patients who will receive IMRT delivered as radical or adjuvant therapy with or without concurrent chemotherapy; Ready to provide written informed consent.
Exclusion: Receiving any other approved or investigational anti-cancer agent than those specified in this study; Patients who are on drugs that could cause oral lesions or are using anticoagulants; Patients who have oral lesions unrelated to treatment or cancer,; Pregnant or breastfeeding female patients.